 Janet Snell-Bergeon
Concepts (517)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 192 | 2026 | 3918 | 17.930 |
Why?
| | Coronary Artery Disease | 44 | 2024 | 747 | 8.080 |
Why?
| | Vascular Calcification | 20 | 2024 | 110 | 7.310 |
Why?
| | Diabetic Nephropathies | 27 | 2025 | 319 | 5.550 |
Why?
| | Hypoglycemic Agents | 37 | 2026 | 1393 | 4.800 |
Why?
| | Blood Glucose | 61 | 2025 | 2335 | 4.790 |
Why?
| | Diabetic Angiopathies | 29 | 2020 | 264 | 4.720 |
Why?
| | Insulin Resistance | 29 | 2026 | 1244 | 4.190 |
Why?
| | Blood Glucose Self-Monitoring | 36 | 2025 | 699 | 3.790 |
Why?
| | Pregnancy in Diabetics | 10 | 2025 | 123 | 2.940 |
Why?
| | Cardiovascular Diseases | 25 | 2026 | 2183 | 2.850 |
Why?
| | Calcinosis | 23 | 2021 | 234 | 2.720 |
Why?
| | Coronary Vessels | 15 | 2023 | 246 | 2.520 |
Why?
| | Adult | 167 | 2026 | 40665 | 2.480 |
Why?
| | Insulin Infusion Systems | 18 | 2026 | 478 | 2.470 |
Why?
| | Biomarkers | 28 | 2026 | 4282 | 2.410 |
Why?
| | Obesity | 20 | 2026 | 3097 | 2.360 |
Why?
| | Albuminuria | 15 | 2022 | 189 | 2.280 |
Why?
| | Insulin | 37 | 2026 | 2510 | 2.280 |
Why?
| | Glucagon-Like Peptides | 5 | 2026 | 69 | 2.020 |
Why?
| | Diabetes Complications | 10 | 2024 | 224 | 1.950 |
Why?
| | Overweight | 4 | 2025 | 609 | 1.930 |
Why?
| | Middle Aged | 125 | 2026 | 36126 | 1.900 |
Why?
| | Diabetes Mellitus, Type 2 | 20 | 2025 | 2578 | 1.820 |
Why?
| | Hypoglycemia | 10 | 2025 | 479 | 1.790 |
Why?
| | Risk Factors | 58 | 2025 | 10857 | 1.720 |
Why?
| | Female | 174 | 2026 | 78636 | 1.700 |
Why?
| | Humans | 221 | 2026 | 145140 | 1.660 |
Why?
| | Male | 155 | 2026 | 72664 | 1.560 |
Why?
| | Uric Acid | 8 | 2018 | 167 | 1.480 |
Why?
| | Glomerular Filtration Rate | 23 | 2025 | 765 | 1.470 |
Why?
| | Diabetic Retinopathy | 6 | 2025 | 209 | 1.460 |
Why?
| | Atherosclerosis | 9 | 2024 | 409 | 1.390 |
Why?
| | Osteoporotic Fractures | 5 | 2020 | 62 | 1.350 |
Why?
| | Pericardium | 3 | 2024 | 59 | 1.330 |
Why?
| | Young Adult | 65 | 2025 | 14176 | 1.290 |
Why?
| | Longitudinal Studies | 17 | 2026 | 2949 | 1.280 |
Why?
| | Disease Progression | 35 | 2025 | 2857 | 1.260 |
Why?
| | Inflammation | 7 | 2026 | 2876 | 1.240 |
Why?
| | Calcium | 11 | 2023 | 1189 | 1.240 |
Why?
| | Body Mass Index | 21 | 2025 | 2437 | 1.170 |
Why?
| | Prospective Studies | 30 | 2025 | 8035 | 1.160 |
Why?
| | C-Reactive Protein | 5 | 2026 | 422 | 1.160 |
Why?
| | Glycopeptides | 3 | 2018 | 44 | 1.120 |
Why?
| | Coronary Disease | 9 | 2015 | 381 | 1.120 |
Why?
| | Weight Loss | 6 | 2026 | 845 | 1.090 |
Why?
| | Adiposity | 7 | 2024 | 532 | 1.090 |
Why?
| | Cross-Sectional Studies | 32 | 2026 | 5886 | 1.010 |
Why?
| | Diet | 4 | 2024 | 1277 | 1.000 |
Why?
| | Hyperglycemia | 8 | 2024 | 379 | 0.950 |
Why?
| | Fruit | 2 | 2024 | 146 | 0.940 |
Why?
| | Cohort Studies | 33 | 2025 | 5988 | 0.940 |
Why?
| | Diet, Mediterranean | 2 | 2023 | 27 | 0.920 |
Why?
| | Glucagon-Like Peptide 1 | 5 | 2025 | 148 | 0.860 |
Why?
| | Case-Control Studies | 28 | 2025 | 3616 | 0.860 |
Why?
| | Blood Coagulation | 1 | 2026 | 274 | 0.830 |
Why?
| | Neurodegenerative Diseases | 1 | 2026 | 140 | 0.830 |
Why?
| | Vascular Stiffness | 6 | 2025 | 486 | 0.800 |
Why?
| | Cactaceae | 1 | 2023 | 5 | 0.780 |
Why?
| | Vegetables | 1 | 2024 | 161 | 0.780 |
Why?
| | Dietary Fiber | 2 | 2023 | 59 | 0.760 |
Why?
| | Apolipoprotein C-III | 3 | 2023 | 11 | 0.750 |
Why?
| | Trace Elements | 1 | 2022 | 52 | 0.700 |
Why?
| | Triglycerides | 10 | 2020 | 520 | 0.690 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2019 | 34 | 0.690 |
Why?
| | Follow-Up Studies | 14 | 2023 | 5411 | 0.690 |
Why?
| | Adiponectin | 6 | 2016 | 241 | 0.680 |
Why?
| | Prediabetic State | 2 | 2023 | 247 | 0.670 |
Why?
| | Bone Density | 8 | 2025 | 484 | 0.650 |
Why?
| | Fibrinogen | 5 | 2026 | 180 | 0.620 |
Why?
| | Cystatin C | 8 | 2015 | 66 | 0.620 |
Why?
| | Adipose Tissue | 6 | 2026 | 644 | 0.610 |
Why?
| | Social Determinants of Health | 1 | 2024 | 307 | 0.610 |
Why?
| | Retrospective Studies | 21 | 2025 | 17247 | 0.610 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 40 | 0.570 |
Why?
| | Uromodulin | 1 | 2018 | 22 | 0.570 |
Why?
| | Apolipoproteins B | 2 | 2015 | 47 | 0.560 |
Why?
| | Depression | 3 | 2024 | 1537 | 0.560 |
Why?
| | Pilot Projects | 12 | 2025 | 1889 | 0.550 |
Why?
| | Cholesterol, HDL | 6 | 2022 | 201 | 0.550 |
Why?
| | Kidney | 7 | 2024 | 1494 | 0.540 |
Why?
| | Cancellous Bone | 1 | 2017 | 22 | 0.540 |
Why?
| | Islets of Langerhans | 2 | 2022 | 846 | 0.530 |
Why?
| | Exercise | 5 | 2026 | 2191 | 0.530 |
Why?
| | Proteomics | 7 | 2022 | 1185 | 0.530 |
Why?
| | Metabolic Syndrome | 1 | 2021 | 360 | 0.520 |
Why?
| | Adolescent | 38 | 2025 | 22479 | 0.510 |
Why?
| | Body Fat Distribution | 1 | 2017 | 46 | 0.510 |
Why?
| | Kidney Function Tests | 3 | 2020 | 156 | 0.510 |
Why?
| | Kidney Diseases | 2 | 2012 | 424 | 0.500 |
Why?
| | Prognosis | 10 | 2026 | 4310 | 0.500 |
Why?
| | Subcutaneous Fat | 1 | 2017 | 79 | 0.490 |
Why?
| | Feeding Behavior | 2 | 2021 | 689 | 0.490 |
Why?
| | Logistic Models | 12 | 2015 | 2133 | 0.490 |
Why?
| | Femur Neck | 4 | 2022 | 62 | 0.490 |
Why?
| | Menopause | 1 | 2019 | 326 | 0.470 |
Why?
| | Fear | 1 | 2019 | 367 | 0.470 |
Why?
| | Muscle, Skeletal | 6 | 2026 | 1789 | 0.470 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2013 | 46 | 0.450 |
Why?
| | Diabetic Ketoacidosis | 3 | 2024 | 209 | 0.450 |
Why?
| | Tomography, X-Ray Computed | 14 | 2019 | 2767 | 0.450 |
Why?
| | Energy Intake | 4 | 2023 | 507 | 0.440 |
Why?
| | Prevalence | 13 | 2025 | 2855 | 0.440 |
Why?
| | Perception | 1 | 2018 | 377 | 0.440 |
Why?
| | Self-Management | 3 | 2024 | 201 | 0.440 |
Why?
| | Autoimmunity | 3 | 2022 | 932 | 0.440 |
Why?
| | Pyrazines | 2 | 2013 | 92 | 0.440 |
Why?
| | Plasminogen Activator Inhibitor 1 | 2 | 2026 | 85 | 0.430 |
Why?
| | Dietary Fats | 3 | 2021 | 308 | 0.430 |
Why?
| | Brachial Artery | 1 | 2016 | 208 | 0.430 |
Why?
| | Triazoles | 2 | 2013 | 187 | 0.410 |
Why?
| | Pregnancy | 14 | 2025 | 7182 | 0.410 |
Why?
| | Renal Insufficiency | 1 | 2016 | 172 | 0.410 |
Why?
| | Up-Regulation | 2 | 2016 | 846 | 0.410 |
Why?
| | Blood Pressure | 10 | 2025 | 1778 | 0.410 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2021 | 661 | 0.410 |
Why?
| | Sex Factors | 9 | 2024 | 2099 | 0.410 |
Why?
| | Fractures, Bone | 1 | 2019 | 426 | 0.410 |
Why?
| | Amino Acids, Branched-Chain | 2 | 2024 | 39 | 0.400 |
Why?
| | Metformin | 1 | 2017 | 327 | 0.400 |
Why?
| | Menarche | 2 | 2011 | 52 | 0.400 |
Why?
| | Pregnancy Outcome | 5 | 2025 | 500 | 0.400 |
Why?
| | Self Report | 1 | 2018 | 867 | 0.400 |
Why?
| | Double-Blind Method | 8 | 2026 | 2057 | 0.380 |
Why?
| | Diglycerides | 3 | 2024 | 61 | 0.380 |
Why?
| | Patient Care Planning | 1 | 2014 | 170 | 0.380 |
Why?
| | Models, Theoretical | 2 | 2015 | 556 | 0.380 |
Why?
| | Postprandial Period | 2 | 2013 | 114 | 0.380 |
Why?
| | Patient Satisfaction | 2 | 2025 | 708 | 0.370 |
Why?
| | Time Factors | 9 | 2024 | 7107 | 0.360 |
Why?
| | Age Factors | 12 | 2026 | 3338 | 0.350 |
Why?
| | Glucagon | 1 | 2013 | 114 | 0.350 |
Why?
| | Ketosis | 2 | 2022 | 12 | 0.350 |
Why?
| | Pancreas, Artificial | 2 | 2023 | 97 | 0.350 |
Why?
| | Child | 25 | 2026 | 22670 | 0.340 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 739 | 0.340 |
Why?
| | Predictive Value of Tests | 12 | 2020 | 2115 | 0.340 |
Why?
| | Cholesterol | 6 | 2014 | 406 | 0.330 |
Why?
| | Treatment Outcome | 9 | 2025 | 11741 | 0.330 |
Why?
| | Polycystic Ovary Syndrome | 2 | 2025 | 186 | 0.330 |
Why?
| | Incidence | 6 | 2021 | 2915 | 0.320 |
Why?
| | Aged | 21 | 2025 | 26096 | 0.320 |
Why?
| | Glucose Clamp Technique | 9 | 2024 | 199 | 0.320 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 6055 | 0.320 |
Why?
| | Lipids | 5 | 2022 | 706 | 0.320 |
Why?
| | Genome-Wide Association Study | 4 | 2026 | 1376 | 0.300 |
Why?
| | Lipoproteins, HDL | 3 | 2024 | 100 | 0.300 |
Why?
| | Proteinuria | 2 | 2010 | 104 | 0.300 |
Why?
| | Colorado | 9 | 2016 | 4538 | 0.290 |
Why?
| | Diabetes Mellitus | 3 | 2024 | 1092 | 0.290 |
Why?
| | Periodontal Diseases | 2 | 2023 | 62 | 0.290 |
Why?
| | Cross-Over Studies | 5 | 2024 | 608 | 0.290 |
Why?
| | Risk Assessment | 7 | 2024 | 3740 | 0.290 |
Why?
| | Haptoglobins | 3 | 2015 | 71 | 0.290 |
Why?
| | Creatinine | 9 | 2022 | 513 | 0.290 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 39 | 0.280 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2026 | 88 | 0.280 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.270 |
Why?
| | Aging | 1 | 2019 | 1962 | 0.270 |
Why?
| | Collagen | 1 | 2010 | 455 | 0.270 |
Why?
| | Vitamins | 2 | 2022 | 182 | 0.260 |
Why?
| | Osteoporosis | 3 | 2020 | 237 | 0.260 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 252 | 0.260 |
Why?
| | Absorptiometry, Photon | 5 | 2022 | 276 | 0.260 |
Why?
| | United States | 9 | 2024 | 16065 | 0.260 |
Why?
| | Anthropometry | 3 | 2017 | 205 | 0.250 |
Why?
| | Software | 2 | 2024 | 678 | 0.250 |
Why?
| | Heart Rate | 1 | 2010 | 855 | 0.240 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2019 | 199 | 0.240 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2026 | 122 | 0.230 |
Why?
| | Contraception | 1 | 2008 | 170 | 0.230 |
Why?
| | Neurofilament Proteins | 1 | 2026 | 78 | 0.230 |
Why?
| | Hypophosphatasia | 1 | 2025 | 5 | 0.230 |
Why?
| | Homocysteine | 1 | 2026 | 152 | 0.230 |
Why?
| | Liver | 5 | 2026 | 1893 | 0.230 |
Why?
| | Early Diagnosis | 2 | 2017 | 251 | 0.230 |
Why?
| | tau Proteins | 1 | 2026 | 105 | 0.230 |
Why?
| | Multivariate Analysis | 5 | 2015 | 1546 | 0.220 |
Why?
| | alpha-Macroglobulins | 1 | 2025 | 25 | 0.220 |
Why?
| | Abdominal Wall | 1 | 2004 | 28 | 0.210 |
Why?
| | Hyperinsulinism | 2 | 2024 | 114 | 0.210 |
Why?
| | Sleep | 2 | 2024 | 887 | 0.210 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 13 | 0.210 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 16 | 0.210 |
Why?
| | Receptors, LDL | 1 | 2024 | 53 | 0.210 |
Why?
| | Apolipoprotein A-I | 1 | 2024 | 39 | 0.210 |
Why?
| | Insulin, Regular, Human | 1 | 2024 | 47 | 0.200 |
Why?
| | Genotype | 8 | 2026 | 1844 | 0.200 |
Why?
| | Protective Factors | 1 | 2024 | 99 | 0.200 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 24 | 0.200 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 244 | 0.200 |
Why?
| | Food Handling | 1 | 2023 | 33 | 0.190 |
Why?
| | Calcium, Dietary | 1 | 2023 | 52 | 0.190 |
Why?
| | Fast Foods | 1 | 2023 | 21 | 0.190 |
Why?
| | Single-Blind Method | 1 | 2024 | 316 | 0.190 |
Why?
| | Glucose | 3 | 2024 | 1048 | 0.190 |
Why?
| | Cholesterol, LDL | 3 | 2015 | 360 | 0.190 |
Why?
| | Sweetening Agents | 1 | 2023 | 57 | 0.190 |
Why?
| | Polymorphism, Genetic | 5 | 2011 | 614 | 0.190 |
Why?
| | Periodontitis | 1 | 2023 | 55 | 0.190 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.180 |
Why?
| | Pulmonary Surfactant-Associated Protein B | 1 | 2022 | 7 | 0.180 |
Why?
| | Plaque, Atherosclerotic | 2 | 2014 | 61 | 0.180 |
Why?
| | Manganese | 1 | 2022 | 55 | 0.180 |
Why?
| | Lipoproteins | 2 | 2016 | 166 | 0.180 |
Why?
| | Mass Spectrometry | 4 | 2017 | 728 | 0.170 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 166 | 0.170 |
Why?
| | Insulins | 1 | 2022 | 38 | 0.170 |
Why?
| | Quality of Life | 2 | 2025 | 3194 | 0.170 |
Why?
| | Copper | 1 | 2022 | 119 | 0.170 |
Why?
| | Inflammasomes | 1 | 2023 | 144 | 0.170 |
Why?
| | Diet Surveys | 1 | 2021 | 90 | 0.170 |
Why?
| | Regression Analysis | 7 | 2014 | 998 | 0.170 |
Why?
| | Peptides | 3 | 2017 | 997 | 0.170 |
Why?
| | Beverages | 1 | 2021 | 68 | 0.170 |
Why?
| | Insulin, Long-Acting | 1 | 2021 | 65 | 0.170 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2020 | 6 | 0.170 |
Why?
| | Intra-Abdominal Fat | 3 | 2017 | 101 | 0.170 |
Why?
| | Meat | 1 | 2021 | 64 | 0.160 |
Why?
| | Automobile Driving | 1 | 2023 | 157 | 0.160 |
Why?
| | Dyslipidemias | 3 | 2015 | 184 | 0.160 |
Why?
| | Genetic Variation | 1 | 2026 | 967 | 0.160 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 847 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2026 | 2351 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2026 | 2136 | 0.160 |
Why?
| | Blindness | 1 | 2020 | 51 | 0.160 |
Why?
| | Vitamin D Deficiency | 2 | 2013 | 190 | 0.150 |
Why?
| | Glomerular Basement Membrane | 1 | 2019 | 8 | 0.150 |
Why?
| | Foam Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | Collagen Type IV | 1 | 2019 | 27 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1109 | 0.150 |
Why?
| | Hip Fractures | 1 | 2020 | 87 | 0.150 |
Why?
| | Proteome | 2 | 2017 | 512 | 0.150 |
Why?
| | Bone Development | 1 | 2019 | 52 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2018 | 3410 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2016 | 2928 | 0.140 |
Why?
| | Premenopause | 1 | 2019 | 125 | 0.140 |
Why?
| | Diet Records | 1 | 2019 | 89 | 0.140 |
Why?
| | Radius | 1 | 2019 | 51 | 0.140 |
Why?
| | Phenotype | 3 | 2024 | 3138 | 0.140 |
Why?
| | Waist Circumference | 2 | 2015 | 143 | 0.140 |
Why?
| | Antioxidants | 1 | 2022 | 550 | 0.140 |
Why?
| | Bone Diseases, Metabolic | 1 | 2019 | 58 | 0.140 |
Why?
| | Sex Distribution | 3 | 2010 | 386 | 0.140 |
Why?
| | Weight Gain | 2 | 2019 | 561 | 0.140 |
Why?
| | Coronary Angiography | 2 | 2014 | 328 | 0.130 |
Why?
| | Linear Models | 4 | 2014 | 844 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.130 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 80 | 0.130 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 47 | 0.130 |
Why?
| | Tibia | 1 | 2019 | 176 | 0.130 |
Why?
| | Hyperlipidemias | 2 | 2011 | 120 | 0.130 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 21 | 0.130 |
Why?
| | Sphingolipids | 1 | 2018 | 83 | 0.130 |
Why?
| | Accelerometry | 1 | 2018 | 118 | 0.130 |
Why?
| | Self Care | 2 | 2018 | 388 | 0.130 |
Why?
| | Hospitalization | 2 | 2024 | 2458 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2024 | 731 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 365 | 0.130 |
Why?
| | Sex Characteristics | 4 | 2018 | 775 | 0.130 |
Why?
| | Retinal Vessels | 1 | 2017 | 77 | 0.120 |
Why?
| | Albumins | 2 | 2016 | 119 | 0.120 |
Why?
| | Age of Onset | 3 | 2026 | 554 | 0.120 |
Why?
| | C-Peptide | 1 | 2018 | 190 | 0.120 |
Why?
| | Autoantigens | 1 | 2019 | 427 | 0.120 |
Why?
| | Sleep Deprivation | 1 | 2019 | 206 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2018 | 202 | 0.120 |
Why?
| | Dietary Supplements | 2 | 2018 | 582 | 0.120 |
Why?
| | Vascular Capacitance | 1 | 2016 | 4 | 0.120 |
Why?
| | Autoantibodies | 2 | 2022 | 1508 | 0.120 |
Why?
| | Hip Joint | 1 | 2017 | 173 | 0.120 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 15 | 0.120 |
Why?
| | Sitagliptin Phosphate | 2 | 2013 | 31 | 0.120 |
Why?
| | Hypertension | 5 | 2015 | 1269 | 0.120 |
Why?
| | Electrophoresis, Capillary | 2 | 2017 | 20 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2024 | 1099 | 0.110 |
Why?
| | Pulse Wave Analysis | 3 | 2023 | 267 | 0.110 |
Why?
| | Infant, Newborn | 5 | 2024 | 6435 | 0.110 |
Why?
| | Vitamin E | 1 | 2015 | 125 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 133 | 0.110 |
Why?
| | Cannabis | 1 | 2022 | 509 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 38 | 0.110 |
Why?
| | Fructose | 1 | 2015 | 132 | 0.110 |
Why?
| | Animals | 11 | 2024 | 37952 | 0.100 |
Why?
| | Mutation | 3 | 2024 | 4071 | 0.100 |
Why?
| | Peptidomimetics | 1 | 2014 | 3 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2019 | 512 | 0.100 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.100 |
Why?
| | Breakfast | 1 | 2014 | 20 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 718 | 0.100 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 297 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1115 | 0.100 |
Why?
| | Risk | 1 | 2016 | 916 | 0.100 |
Why?
| | Goals | 1 | 2015 | 184 | 0.100 |
Why?
| | HLA-DR2 Antigen | 1 | 2012 | 8 | 0.090 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 285 | 0.090 |
Why?
| | Bromocriptine | 2 | 2022 | 31 | 0.090 |
Why?
| | Chromatography, Liquid | 2 | 2012 | 450 | 0.090 |
Why?
| | Mice | 9 | 2024 | 18303 | 0.090 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 55 | 0.090 |
Why?
| | HLA-DQ beta-Chains | 1 | 2012 | 58 | 0.090 |
Why?
| | Fasting | 1 | 2014 | 276 | 0.090 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 456 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 110 | 0.090 |
Why?
| | Early Medical Intervention | 1 | 2012 | 62 | 0.090 |
Why?
| | Puberty, Delayed | 1 | 2011 | 10 | 0.090 |
Why?
| | Menstruation Disturbances | 1 | 2011 | 13 | 0.090 |
Why?
| | Models, Statistical | 1 | 2015 | 671 | 0.090 |
Why?
| | Allylamine | 1 | 2011 | 6 | 0.080 |
Why?
| | Matrix Metalloproteinases | 1 | 2011 | 95 | 0.080 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.080 |
Why?
| | Angiopoietin-1 | 1 | 2010 | 12 | 0.080 |
Why?
| | Angiopoietin-2 | 1 | 2010 | 15 | 0.080 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2010 | 78 | 0.080 |
Why?
| | Cardiovascular System | 1 | 2012 | 138 | 0.080 |
Why?
| | ROC Curve | 3 | 2020 | 617 | 0.080 |
Why?
| | Observer Variation | 1 | 2011 | 356 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 586 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 221 | 0.080 |
Why?
| | Models, Biological | 3 | 2015 | 1763 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 403 | 0.080 |
Why?
| | Hypolipidemic Agents | 1 | 2010 | 89 | 0.080 |
Why?
| | Glucose Tolerance Test | 2 | 2024 | 360 | 0.080 |
Why?
| | Rats | 3 | 2015 | 5582 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 775 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2018 | 8318 | 0.080 |
Why?
| | Sarcolemma | 2 | 2020 | 35 | 0.070 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 37 | 0.070 |
Why?
| | Anticholesteremic Agents | 1 | 2011 | 155 | 0.070 |
Why?
| | Puberty | 1 | 2010 | 136 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 852 | 0.070 |
Why?
| | Athletes | 2 | 2024 | 421 | 0.070 |
Why?
| | Cytosol | 2 | 2020 | 212 | 0.070 |
Why?
| | Leptin | 1 | 2010 | 248 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1138 | 0.070 |
Why?
| | Alleles | 3 | 2018 | 888 | 0.070 |
Why?
| | Acute Disease | 2 | 2024 | 1035 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Algorithms | 1 | 2015 | 1845 | 0.070 |
Why?
| | Fatty Acids | 1 | 2010 | 457 | 0.060 |
Why?
| | Electrocardiography | 1 | 2010 | 664 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 235 | 0.060 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1995 | 0.060 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 264 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1058 | 0.060 |
Why?
| | Life Style | 1 | 2009 | 483 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2009 | 239 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 80 | 0.060 |
Why?
| | Gene Frequency | 3 | 2018 | 484 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Mass Screening | 2 | 2013 | 1354 | 0.060 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2021 | 154 | 0.060 |
Why?
| | Reference Values | 4 | 2010 | 798 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 229 | 0.060 |
Why?
| | Extracellular Matrix | 1 | 2010 | 561 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2010 | 775 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 531 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 442 | 0.060 |
Why?
| | Registries | 3 | 2020 | 2401 | 0.060 |
Why?
| | Major Histocompatibility Complex | 1 | 2026 | 233 | 0.050 |
Why?
| | Alkaline Phosphatase | 1 | 2025 | 144 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2024 | 3114 | 0.050 |
Why?
| | Apolipoprotein B-100 | 1 | 2024 | 13 | 0.050 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.050 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 517 | 0.050 |
Why?
| | Cost Savings | 1 | 2024 | 86 | 0.050 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2024 | 22 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2024 | 68 | 0.050 |
Why?
| | Carnitine | 1 | 2024 | 91 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2024 | 89 | 0.050 |
Why?
| | Drug Approval | 1 | 2024 | 93 | 0.050 |
Why?
| | Fatty Liver | 1 | 2026 | 253 | 0.050 |
Why?
| | Ceramides | 1 | 2024 | 117 | 0.050 |
Why?
| | Odds Ratio | 3 | 2011 | 1082 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 374 | 0.050 |
Why?
| | Mice, Inbred NOD | 2 | 2015 | 613 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 147 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1415 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 376 | 0.050 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 160 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1270 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2023 | 75 | 0.050 |
Why?
| | Cathepsin D | 1 | 2022 | 20 | 0.050 |
Why?
| | Infant | 2 | 2017 | 10060 | 0.050 |
Why?
| | Smoking | 1 | 2009 | 1470 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 836 | 0.050 |
Why?
| | Patient Admission | 1 | 2024 | 220 | 0.050 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.040 |
Why?
| | Postpartum Period | 1 | 2025 | 372 | 0.040 |
Why?
| | Ketone Bodies | 1 | 2021 | 16 | 0.040 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 2021 | 17 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 640 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2024 | 283 | 0.040 |
Why?
| | Lipase | 1 | 2002 | 75 | 0.040 |
Why?
| | Glycerol | 2 | 2012 | 90 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2662 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 291 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 77 | 0.040 |
Why?
| | Technology | 1 | 2021 | 96 | 0.040 |
Why?
| | Ketones | 1 | 2021 | 50 | 0.040 |
Why?
| | Diabetes, Gestational | 1 | 2005 | 305 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1066 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2020 | 88 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2023 | 294 | 0.040 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4552 | 0.040 |
Why?
| | Body Weight | 1 | 2024 | 969 | 0.040 |
Why?
| | Aryldialkylphosphatase | 1 | 2019 | 17 | 0.040 |
Why?
| | Mitochondria, Muscle | 1 | 2020 | 120 | 0.040 |
Why?
| | Physical Endurance | 1 | 2020 | 276 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2024 | 2185 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 48 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 571 | 0.040 |
Why?
| | Insulin Aspart | 1 | 2018 | 30 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2018 | 80 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 43 | 0.030 |
Why?
| | Cytokines | 2 | 2017 | 2048 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5972 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 168 | 0.030 |
Why?
| | Retinal Artery | 1 | 2017 | 17 | 0.030 |
Why?
| | Retinal Vein | 1 | 2017 | 14 | 0.030 |
Why?
| | Injections | 1 | 2018 | 198 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 134 | 0.030 |
Why?
| | Postmenopause | 1 | 2020 | 391 | 0.030 |
Why?
| | Fundus Oculi | 1 | 2017 | 89 | 0.030 |
Why?
| | Health Behavior | 1 | 2023 | 787 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2020 | 587 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 369 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2002 | 1244 | 0.030 |
Why?
| | Canada | 1 | 2018 | 429 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2025 | 1188 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2017 | 33 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 177 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2018 | 571 | 0.030 |
Why?
| | Photography | 1 | 2017 | 119 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 459 | 0.030 |
Why?
| | Blood Banks | 1 | 2016 | 50 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1742 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 514 | 0.030 |
Why?
| | Area Under Curve | 1 | 2017 | 329 | 0.030 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 162 | 0.030 |
Why?
| | Health Personnel | 1 | 2022 | 749 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1145 | 0.030 |
Why?
| | Autophagy-Related Proteins | 1 | 2015 | 46 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 380 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2015 | 167 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2015 | 119 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2015 | 118 | 0.030 |
Why?
| | HLA-DQ Antigens | 1 | 2015 | 174 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 387 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 145 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1079 | 0.030 |
Why?
| | Vasodilation | 1 | 2017 | 521 | 0.030 |
Why?
| | Purines | 1 | 2015 | 186 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 49 | 0.020 |
Why?
| | Survival Analysis | 1 | 2017 | 1371 | 0.020 |
Why?
| | Insulin-Secreting Cells | 1 | 2018 | 392 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 309 | 0.020 |
Why?
| | Primary Prevention | 1 | 2015 | 218 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 499 | 0.020 |
Why?
| | Cause of Death | 1 | 2015 | 470 | 0.020 |
Why?
| | Molecular Weight | 1 | 2012 | 312 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 784 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 51 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Colesevelam Hydrochloride | 1 | 2011 | 6 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2015 | 673 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2015 | 2127 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 992 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2013 | 252 | 0.020 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 16 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2881 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1261 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 898 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 427 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 19 | 0.020 |
Why?
| | Finland | 1 | 2009 | 78 | 0.020 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.020 |
Why?
| | Cysts | 1 | 2010 | 112 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1506 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2011 | 279 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 151 | 0.020 |
Why?
| | Proteins | 1 | 2015 | 1022 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.020 |
Why?
| | Europe | 1 | 2009 | 416 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 133 | 0.020 |
Why?
| | Spleen | 1 | 2010 | 507 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2010 | 346 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 100 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 517 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 1300 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2010 | 529 | 0.020 |
Why?
| | Patient Compliance | 1 | 2011 | 587 | 0.020 |
Why?
| | Body Composition | 1 | 2010 | 690 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 784 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1505 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 733 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2524 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2010 | 754 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 302 | 0.010 |
Why?
| | Maternal Age | 1 | 2005 | 127 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 402 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11835 | 0.010 |
Why?
| | Signal Transduction | 1 | 2015 | 5208 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1433 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1351 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3892 | 0.010 |
Why?
|
|
Snell-Bergeon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|